Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PCSK9 inhibitors

- PMLiVE

FDA clears Amgen’s Corlaner for heart failure

It is the firm’s first cardiovascular product to gain approval

- PMLiVE

AstraZeneca and PatientsLikeMe team up on real-world data

Two groups hoping to harness the power of the patient forum network

- PMLiVE

Going the distance

Sanofi’s Pascale Witz on driving through change

- PMLiVE

Top biotech firms saw sales jump in 2014

But rate of growth slowing from the past five years according to new analysis

- PMLiVE

Amgen gets EU nod for wider use of Vectibix

US biotech’s cancer therapy can now be used in a first-line setting

- PMLiVE

Amgen gets quick US review for Kyprolis

To be considered as a second-line therapy for multiple myeloma

- PMLiVE

Novo Nordisk will refile rejected diabetes duo in US

Danish firm hopes it will be second time lucky with key treatment

- PMLiVE

Icelandic genome study yields new disease genes

Nature Medicine study focuses on the probability of developing Alzheimer’s

- PMLiVE

Novo Nordisk sheds autoimmune portfolio to BMS

Continues the trend of pharma buying up unwanted assets from rival firms

- PMLiVE

Sanofi on track to refile Lyxumia in US

Study showed drug was equivalent to placebo in cardiovascular safety

- PMLiVE

Cancer Drugs Fund cull ‘won’t save NHS money’

New survey also finds that oncologists believe the cuts will ‘worsen patient outcomes’

Sanofi names Robert Castaigne as audit committee chairman

He succeeds Dr Klaus Pohle

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links